ModifiedUnitedHealthcarePolicy CS017KY.11

Chromosome Microarray Testing (Non-Oncology Conditions) (for Kentucky Only)

Defines medical necessity and coverage for chromosome microarray testing (aCGH and/or SNP array) for non-oncology indications for UnitedHealthcare members in Kentucky.

Policy Summary

PayerUnitedHealthcare

PolicyChromosome Microarray Testing (Non-Oncology Conditions) (for Kentucky Only)

Policy CodePolicy CS017KY.11

Change TypeICD-10 code updates (added 4, removed 2)

Effective Date11/01/2025

Next Review DateN/A

Key ActionDocument that genetic counseling was offered or provided and submit applicable fetal/maternal ICD-10 diagnosis codes when requesting coverage for CMA.

SourceLink

POLICY UPDATE CHANGES

Updated list of applicable ICD-10 diagnosis codes to reflect annual edits, adding Q89.89, Q99.89, QA0.0159, and QA0.8 and removing Q89.8 and Q99.8.

Archived previous policy version CS017KY.10.

KentuckyRegion

aCGH / SNPMethods covered

Prenatal & pediatricPrimary populations

~25+ICD-10 codes (approx)

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

inv-01: Medically necessary indications

Chromosome microarray testing using aCGH and/or SNP array is proven and medically necessary for the following:

Prenatal evaluation: Evaluation of an embryo/fetus in any of: intrauterine fetal demise or stillbirth; testing products of conception following pregnancy loss; individuals undergoing invasive prenatal testing (amniocentesis, chorionic villus sampling, or fetal tissue sampling).

Supports prenatal indications

Postnatal developmental and structural indications: Evaluation of individuals with one or more of: autism spectrum disorder (ASD); isolated severe congenital heart disease; multiple anomalies not specific to a Well‑Delineated Genetic Syndrome and not identifiable by clinical evaluation alone; developmental delay/intellectual disability when a specific syndrome is not suspected.

Supports pediatric/neurodevelopmental indications

Familial follow‑up testing: Evaluation of a biological parent or sibling of a fetus or child with an abnormal or equivocal chromosome microarray finding to assist interpretation and recurrence risk assessment.

Supports familial follow‑up testing

inv-02: Not medically necessary for other indications

Not medically necessary: Chromosome microarray testing using aCGH or SNP array is unproven and not medically necessary for all other populations and conditions not explicitly listed as medically necessary due to insufficient evidence of efficacy.

Explicit negative coverage stance for unspecified/other indications

inv-03: Diagnostic utility of CMA

Coverage considerations and clinical utility statements included in this section

General CMA utility: CMA (aCGH or SNP array) detects deletions and duplications (copy number variants) across the genome and offers higher resolution for unbalanced chromosomal abnormalities than conventional karyotype; it may be targeted or genome‑wide. CMA may identify variants of uncertain significance and cannot reliably detect balanced rearrangements.

Diagnostic strengths and limitations

inv-04: Obstetric/pregnancy indications

Evidence summaries for obstetric indications

Obstetric evidence summary: Multiple observational studies and systematic reviews report higher diagnostic yield of CMA versus karyotype in fetuses with structural malformations, congenital heart defects, and fetal growth restriction when structural anomalies are present; study limitations include single‑center cohorts, selection bias, and variable sample sizes.

Individual studies cited: Li et al. (FGR), Nguyen et al. (SNP array in IUGR), Lu/Ye et al. (CHD)

inv-05: Prenatal indications where CMA is recommended/first-tier

Covered when ANY of the following guideline-supported prenatal indications are present:

Fetal structural abnormalities (primary test): CMA is recommended as the primary test (may replace conventional karyotype) for prenatal diagnosis when one or more major fetal structural abnormalities are identified on ultrasound and invasive prenatal testing is being performed.

ACOG/SMFM practice bulletin and committee opinion

Stillbirth/POC evaluation: CMA of fetal tissue or products of conception is recommended in the evaluation of intrauterine fetal demise or stillbirth when further cytogenetic analysis is desired because it has higher success rates on nonviable tissue and improved detection compared with karyotype.

ACOG/SMFM Obstetric Care Consensus

Abnormal NIPS follow‑up: CMA performed on CVS or amniocentesis may be used to confirm abnormal NIPS results or as a reflex when karyotype is normal, particularly when NIPS suggests a small CNV.

ACMG practice resource (Cherry et al., 2017)

inv-06: Cardiac anomalies

Covered when ALL of the following are met:

CHD_CMA: Fetus with a congenital heart defect (CHD) identified on ultrasound/echocardiography; consider CMA, particularly when CHD is non‑isolated or when extracardiac anomalies are present, because diagnostic yield is higher in non‑isolated CHD and in specific subtypes (e.g., conotruncal defects, TOF).

Systematic reviews/meta‑analyses show incremental yield and higher detection in non‑isolated CHD

inv-07: Other fetal structural or ultrasound findings

Consider CMA when ANY of the following are present:

Increased nuchal translucency / cystic hygroma: Increased nuchal translucency (NT) or cystic hygroma (e.g., NT ≥ 3.5 mm) — CMA provides incremental diagnostic yield and should be considered along with other targeted testing (e.g., RASopathy panel) and possibly exome sequencing for select cases.

Meta‑analyses and case series report incremental yield

Mixed structural anomalies or multiple soft markers on ultrasound — CMA yields are higher than for isolated minor findings and CMA is considered a first‑tier test for structural anomalies.

Mastromoro et al. systematic reviews

Short long bones: Fetal short long bones on ultrasound — CMA yield is increased relative to background risk and should be offered when diagnosed, especially for certain severity/timeframe thresholds reported in studies.

Geffen et al.; cohort data support increased yield

inv-08: Pregnancy loss and products of conception (POC)

Covered when ALL of the following are met:

POC_CMA: Chromosomal microarray analysis of products of conception (POC) provides higher informative rates and identifies additional pathogenic CNVs compared with karyotype in pregnancy losses; CMA is recommended when cytogenetic analysis of POC is desired to evaluate causes of pregnancy loss or to assess recurrence risk.

Systematic reviews and meta‑analyses report higher informative rates and pCNV detection in POC

inv-09: Covered indications and clinical criteria

Coverage aligned with specialty guidance — CMA is considered medically indicated in the following distinct clinical scenarios:

Prenatal clinical scenarios: Offer CMA for prenatal cases with fetal structural anomalies, polyhydramnios, unexplained early‑onset fetal growth restriction (<32 weeks), multiple soft markers (when no placental basis for FGR is indicated), or when invasive diagnostic testing is being performed for major anomalies.

Supported by SMFM, SOGC, SOGC/CCMG, ACOG/SMFM

Postnatal developmental/neurodevelopmental scenarios: CMA is recommended as a first‑tier diagnostic test for individuals with developmental delay/global developmental delay, intellectual disability, autism spectrum disorder, multiple congenital anomalies, or apparently non‑syndromic DD/ID.

Supported by ACMG, ISCA, AAP, CCMG

Targeted testing first when syndrome suspected: When a recognizable genetic syndrome is strongly suspected based on clinical evaluation (e.g., Fragile X, Rett, PTEN, tuberous sclerosis, Prader‑Willi, Angelman, Down syndrome), perform targeted testing for that syndrome first; if targeted testing is negative, proceed to CMA (and Fragile X where indicated).

inv-10: Professional guidance

Supporting professional guidance for CMA use

ISCA/consensus guidance: The ISCA Consortium and multiple professional societies recommend that CMA be the first‑tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies; follow‑up gene‑specific testing may be considered if CMA is negative.

ISCA consensus (Miller et al., 2010) and corroborating society guidance

All indications not explicitly listed as medically necessary in this policy are considered unproven and not medically necessary. Chromosome microarray testing using aCGH or SNP array is designated as medically necessary only for the specific prenatal and postnatal scenarios enumerated in the Coverage Rationale; requests outside those listed populations and conditions may be denied as investigational due to insufficient evidence of clinical benefit.

Chromosomal microarray analysis (CMA) using aCGH or SNP arrays does not reliably detect balanced chromosomal rearrangements (translocations or inversions that have no net gain or loss of genetic material). Because CMA detects copy number changes, it may miss balanced rearrangements and therefore is not appropriate when the clinical question is specifically to identify balanced structural changes.

Society for Maternal-Fetal Medicine guidance indicates that the use of CMA is not recommended as a first-line test to evaluate first trimester pregnancy losses because available data are limited. When evaluating first trimester losses, clinicians should consider guideline recommendations and the limitations of current evidence before selecting CMA as the initial diagnostic modality.

Professional society guidance (SMFM; SOGC/CCMG) consistently notes that CMA is not recommended as a first-line test for first trimester pregnancy loss given limited data, and that routine use in pregnancies at low risk for structural anomaly is not advised. For prenatal settings, these guidelines emphasize targeted application of CMA in cases with structural anomalies, stillbirth, or other higher-risk indications and recommend genetic counseling to support informed decision-making.

Information about U.S. Food and Drug Administration actions is provided for context only: FDA approval or clearance alone does not establish coverage. Coverage determinations require application of plan, federal/state, and contractual requirements in addition to clinical policy criteria.

Chromosome microarray testing using array-CGH or SNP array is considered unproven and not medically necessary for populations and clinical conditions that are not specifically listed as medically necessary in this policy due to insufficient evidence of efficacy.

Because CMA identifies copy number variants, it is not appropriate when the clinical aim is to detect balanced chromosomal rearrangements (e.g., balanced translocations or inversions), which do not produce net copy number changes and therefore may not be detected by CMA platforms.

CMA would not be considered medically necessary when a clinical evaluation provides a readily apparent diagnosis of a specific disorder or syndrome. Model coverage and professional guidance indicate that when a recognized syndrome is clinically apparent and targeted testing is appropriate, targeted syndrome-specific testing should be performed first, and CMA reserved if targeted testing is nondiagnostic.

This policy provides FDA information for reference only; FDA approval alone does not establish coverage. Coverage decisions must apply plan, federal/state, and contractual terms in addition to the clinical criteria set forth in this document.

Covered Indications (Detailed Scenarios)

inv-64: Prenatal evaluation including intrauterine fetal demise/stillbirth, products of conception after pregnancy loss, and invasive prenatal testing (amniocentesis, CVS, fetal tissue sampling).

Prenatal evaluation inclusions: Prenatal evaluation including intrauterine fetal demise/stillbirth, products of conception after pregnancy loss, and invasive prenatal testing (amniocentesis, CVS, fetal tissue sampling) — aCGH and/or SNP array are considered proven and medically necessary in these scenarios.

Supports indicated prenatal testing pathways

inv-65: Individuals with ASD, isolated severe congenital heart disease, multiple anomalies not specific to a well-delineated genetic syndrome, or developmental delay/intellectual disability, when a specific syndrome is not suspected.

Neurodevelopmental and congenital cardiac indications: Individuals with autism spectrum disorder (ASD), isolated severe congenital heart disease, multiple anomalies not specific to a well‑delineated genetic syndrome, or developmental delay/intellectual disability when a specific syndrome is not suspected — CMA is indicated as a diagnostic test when clinical evaluation does not identify a specific syndrome.

Postnatal first‑tier recommendation for these indications

Procedure and Diagnosis Codes

Covered/Referenced Procedure Codesmixed

0156U	Copy number (e.g., intellectual disability, dysmorphology), sequence analysis.
0209U	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities.
81228	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number variants, comparative genomic hybridization [CGH] microarray analysis.
81229	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and single nucleotide polymorphism (SNP) variants, comparative genomic hybridization (CGH) microarray analysis.
81349	Cytogenomic (genome-wide) analysis for constitutional chromosomal abnormalities; interrogation of genomic regions for copy number and loss-of-heterozygosity variants, low-pass sequencing analysis.
81479	Unlisted molecular pathology procedure.
S3870	Comparative genomic hybridization (CGH) microarray testing for developmental delay, autism spectrum disorder and/or intellectual disability.

Referenced Diagnosis Codes (selected examples from long list)ICD-10

F70	Mild intellectual disabilities
F71	Moderate intellectual disabilities.
F72	Severe intellectual disabilities.
F73	Profound intellectual disabilities.
F78.A1	SYNGAP1-related intellectual disability.
F78.A9	Other genetic related intellectual disability.
F79	Unspecified intellectual disabilities.
F80.0	Phonological disorder.
F84.0	Autistic disorder.
N96	Recurrent pregnancy loss.

1–10 of 13

1/2

Applicable ICD-10 codes (sample from O35 group)ICD-10

O35.12X9	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 18, other fetus
O35.13X0	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, not applicable or unspecified
O35.13X1	Maternal care for (suspected) chromosomal abnormality in fetus, Trisomy 21, fetus 1

Applicable ICD-10 codes (continued O35 group)ICD-10

O35.14X0	Maternal care for (suspected) chromosomal abnormality in fetus, Turner Syndrome, not applicable
O35.15X1	Maternal care for (suspected) chromosomal abnormality in fetus, sex chromosome abnormality, fetus 1
O35.19X0	Maternal care for (suspected) chromosomal abnormality in fetus, other chromosomal abnormality, not applicable or unspecified

Applicable ICD-10 codes (O35/O36 variants)ICD-10

O35.2XX0	Maternal care for (suspected) hereditary disease in fetus, not applicable or unspecified
O35.BXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal cardiac anomalies, not applicable or unspecified
O35.CXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal pulmonary anomalies, not applicable or unspecified

Applicable ICD-10 codes (O36/P codes)ICD-10

O35.EXX0	Maternal care for other (suspected) fetal abnormality and damage, fetal genitourinary anomalies, not applicable or unspecified
O36.4XX0	Maternal care for intrauterine death, not applicable or unspecified
P02.9	Newborn affected by abnormality of membranes, unspecified

Applicable ICD-10 codes (congenital cardiac malformations)ICD-10

Q20.1	Double outlet right ventricle
Q21.0	Ventricular septal defect
Q21.3	Tetralogy of Fallot

Applicable ICD-10/QA codes (trisomies, deletions, syndromes)ICD-10

Q90.0	Trisomy 21, nonmosaicism (meiotic nondisjunction)
Q91.0	Trisomy 18, nonmosaicism (meiotic nondisjunction)
Q93.4	Deletion of short arm of chromosome 5
Q93.51	Angelman syndrome
Q93.52	Phelan-McDermid syndrome
QA0.0159	Neurodevelopmental disorder, related to other genes associated with transcription and gene expression

Regulatory / laboratorymixed

No codes listed

Applicable ICD-10 diagnosis codes (edited)ICD-10

Q89.89	ICD-10 code added in applicable codes list
Q99.89	ICD-10 code added in applicable codes list
QA0.0159	ICD-10 code added in applicable codes list
QA0.8	ICD-10 code added in applicable codes list
Q89.8	ICD-10 code removed in applicable codes list
Q99.8	ICD-10 code removed in applicable codes list

Prenatal VUS reporting cutoffs

Prenatal VUS reporting cutoff (deletions)Do not report variants of uncertain significance (VUS) smaller than 500 Kb deletions in the prenatal setting.

Prenatal VUS reporting cutoff (duplications)Do not report VUS smaller than 1 Mb duplications in the prenatal setting.

Reporting larger VUSVUS above these size thresholds should be reported only if there is significant evidence suggesting pathogenicity.

Regulatory

Regulatory requirement

Provider Actions, Prior Authorization, and Documentation

Prior Authorization

Code references (may affect prior authorization) — Procedure codes listed are provided for reference and may be subject to benefit, prior authorization, or coverage determination per contract.

Procedure and diagnosis codes referenced in this policy are provided for informational purposes and may affect prior authorization and coverage determinations. Inclusion of a code does not guarantee payment; verify benefit, prior authorization, and coverage rules under the member's federal, state, or contractual plan.

Codes may be subject to benefit limits, prior authorization, or exclusion per contract.
When submitting a request, include the specific procedure codes (e.g., 0156U, 0209U, 81228, 81229, 81349, 81479, S3870) and the applicable ICD-10 diagnosis code(s).

Documentation Required

Use applicable ICD-10 codes — Providers should submit the applicable fetal/maternal ICD-10 diagnosis codes listed when requesting coverage for CMA; prior authorization requests should include these codes.

Providers should submit the most applicable fetal and maternal ICD-10 diagnosis codes when requesting coverage for chromosome microarray analysis (CMA). Use O35 series codes for suspected fetal chromosomal abnormalities and specific postnatal/clinical ICD-10 codes (e.g., F70 for intellectual disability) as appropriate.

Eligibility and When Testing of Family Members Is Covered

Evaluation of a biological parent or sibling is covered when testing is performed to clarify an abnormal or equivocal chromosome microarray result in a fetus or child; parental or familial testing can be essential for variant interpretation and clinical decision-making and should be documented in the patient record.

When a fetus or child has an abnormal or equivocal CMA result, testing of biological parents or siblings is considered part of appropriate clinical evaluation to determine inheritance and clarify pathogenicity; such familial testing is a recognized component of interpretation and is covered when performed for this purpose.

Parental or sibling evaluation is covered to assist in interpretation of variants of uncertain significance or to confirm segregation of a pathogenic copy number variant detected in the proband; clinicians should document the indication for familial testing in the medical record.

In some clinical contexts (for example, evaluation of certain congenital heart defects), CMA may replace conventional karyotype as the preferred diagnostic test because CMA provides higher resolution for submicroscopic copy number variants; where karyotype is normal but additional evaluation is warranted, CMA is an appropriate next step.

Not Covered / Unproven Indications

Chromosome microarray testing using aCGH or SNP array for populations and clinical conditions not specified as medically necessary in this policy is considered unproven and not medically necessary and may be denied when requested for those indications.

Testing specifically intended to identify balanced chromosomal rearrangements is not appropriate for CMA platforms because CMA cannot reliably detect balanced translocations or inversions; alternative cytogenetic methods (e.g., conventional karyotype or targeted FISH) should be considered when detection of balanced rearrangements is required.

CMA is not recommended as first-line testing for first trimester pregnancy losses based on limited data; clinicians should follow guideline recommendations and consider the gestational age, clinical context, and alternative testing approaches when evaluating early pregnancy loss.

Use of CMA as a first-line test for first trimester pregnancy loss is not recommended by specialty guidance and is not considered routine for pregnancies at low risk for structural anomalies; indications for CMA in pregnancy should align with guideline-defined higher-risk scenarios (e.g., structural anomalies, stillbirth, or unexplained early-onset FGR).

The source document does not list specific genetic tests that are categorically not covered by code, but it reiterates that FDA clearance or approval is informational only and does not by itself determine coverage; coverage decisions depend on application of this policy and the member's contractual and regulatory requirements.

Background and Definitions

Chromosome microarray testing (including aCGH and SNP arrays) detects genome-wide copy number variants (deletions and duplications) and regions of homozygosity and is used for prenatal evaluation (including stillbirth/POC and invasive prenatal diagnosis) and for postnatal assessment of developmental disorders, autism spectrum disorder, intellectual disability, and multiple congenital anomalies. CMA provides higher resolution than conventional karyotype for unbalanced chromosomal abnormalities but may identify variants of unknown significance, can yield false positives requiring follow-up, and does not reliably detect balanced rearrangements. Pre-test genetic counseling is strongly recommended and testing should be performed and interpreted in the context of clinical indications and applicable regulatory frameworks (CLIA); FDA clearance is informational and not determinative for coverage.

Developmental Delay

DefinitionDevelopmental Delay: used to describe children younger than 5 years who present with delays in attainment of developmental milestones at the expected age.

Age noteApplies specifically to children younger than 5 years of age for this terminology (Moeschler and Shevell, 2014, reaffirmed 2019).

Context of useUsed in policy to identify indications for postnatal CMA when developmental milestones are delayed and a specific syndrome is not suspected.

Policy Revision History and Material Changes

2025-11-01ICD-10 code updateLatest

Updated list of applicable ICD-10 diagnosis codes: added Q89.89, Q99.89, QA0.0159, and QA0.8; removed Q89.8 and Q99.8.

Summary of changes

Note

Material change

Administrative notes and prior version

Note

Policy use and applicability

Policy Summary

PayerUnitedHealthcare

PolicyChromosome Microarray Testing (Non-Oncology Conditions) (for Kentucky Only)

Policy CodePolicy CS017KY.11

Change TypeICD-10 code updates (added 4, removed 2)

Effective Date11/01/2025

Next Review DateN/A

Key ActionDocument that genetic counseling was offered or provided and submit applicable fetal/maternal ICD-10 diagnosis codes when requesting coverage for CMA.

SourceLink

On This Page

FGR with malformations or early onset: Offer CMA when fetal growth restriction (FGR/IUGR) is present with structural malformations, polyhydramnios, multiple soft markers, or when unexplained isolated early‑onset FGR is diagnosed before 32 weeks of gestation.

AACAP/ACMG recommendations

Genetic counseling and reporting considerations: Pre‑ and post‑test genetic counseling by trained personnel is recommended; parental preferences for reporting incidental/secondary findings should be obtained; limit prenatal reporting of small VUS per guideline thresholds.

SOGC/CCMG and other specialty recommendations (e.g., VUS cutoffs)

inv-66: Evaluation of a biological parent or sibling of a fetus/child with an abnormal or equivocal chromosome microarray result.

Familial testing for interpretation: Evaluation of a biological parent or sibling of a fetus/child with an abnormal or equivocal chromosome microarray result to aid interpretation (e.g., determine de novo vs inherited status of a CNV) and recurrence risk assessment.

Parental/sibling testing covered when performed for interpretation of proband CMA result

inv-67: Prenatal diagnosis for fetuses with structural malformations, congenital heart defects, or fetal growth restriction, and postnatal evaluation of congenital anomalies, developmental delay, intellectual disability, and neurodevelopmental disorders.

Prenatal & postnatal structural indications: Prenatal diagnosis for fetuses with structural malformations, congenital heart defects, or fetal growth restriction, and postnatal evaluation of congenital anomalies, developmental delay, intellectual disability, and neurodevelopmental disorders — CMA demonstrates higher diagnostic yield compared with karyotype in multiple studies and is recommended in these contexts.

Evidence from multiple observational studies and meta‑analyses

inv-68: Fetal structural abnormalities detected on ultrasound (CMA as primary test) — Includes isolated and non-isolated anomalies; higher yield in non-isolated cases.

Fetal structural abnormalities on ultrasound: Fetal structural abnormalities detected on ultrasound — CMA is the primary recommended test for patients undergoing invasive prenatal diagnosis for structural anomalies and has higher diagnostic yield in non‑isolated cases.

ACOG/SMFM and specialty guidance support CMA as primary test

inv-69: Stillbirth or intrauterine fetal death (POC testing) — CMA preferred over karyotype for stillbirth evaluation due to higher success rates on nonviable tissue.

Stillbirth/POC preferred testing: Stillbirth or intrauterine fetal death — CMA is preferred over karyotype for evaluation of POC or fetal tissue due to higher test success with nonviable tissue and improved detection of causative anomalies.

ACOG/SMFM Obstetric Care Consensus and supporting evidence

inv-70: Congenital heart defects (CHD), especially non-isolated CHD or CHD with extracardiac anomalies — Higher diagnostic yield; consider first-tier testing.

CHD first‑line consideration: Congenital heart defects (CHD), especially non‑isolated CHD or CHD with extracardiac anomalies — CMA has higher diagnostic yield than karyotype and should be considered as first‑tier testing, particularly when karyotype is normal.

Meta‑analysis and large cohort studies demonstrate increased detection in CHD, especially non‑isolated cases

inv-71: Fetal growth restriction (FGR) with malformations or unexplained early-onset FGR (<32 weeks) — SMFM and SOGC recommend offering CMA in these settings.

FGR indications: Fetal growth restriction (FGR) with malformations or unexplained early‑onset FGR (<32 weeks) — offer CMA, particularly when structural anomalies, polyhydramnios, or multiple soft markers are present, per SMFM and SOGC guidance.

Specialty society recommendations (SMFM, SOGC)

inv-72: Abnormal NIPS with suspected small CNV or discordant findings — CMA on CVS or amniocentesis may be used for confirmatory diagnosis or as reflex testing.

Abnormal NIPS follow‑up: Abnormal noninvasive prenatal screening (NIPS) results suggesting small CNVs or discordant findings — CMA on CVS or amniocentesis may be used for confirmatory diagnosis or as a reflex when karyotype is normal.

ACMG practice resource guidance

inv-73: Individuals with developmental delay/global developmental delay, intellectual disability, autism spectrum disorder, multiple congenital anomalies, or apparently non-syndromic DD/ID.

Developmental and neurodevelopmental indications: Individuals with developmental delay/global developmental delay, intellectual disability, autism spectrum disorder, multiple congenital anomalies, or apparently non‑syndromic DD/ID — CMA is recommended as a first‑tier diagnostic test by multiple professional societies (ACMG, ISCA, AAP, CCMG).

Society recommendations and technical standards

inv-74: Prenatal cases with fetal structural anomalies, polyhydramnios, unexplained early-onset fetal growth restriction (<32 weeks), or multiple soft markers when no placental basis for FGR is indicated.

Prenatal scenarios per societies: Prenatal cases with fetal structural anomalies, polyhydramnios, unexplained early‑onset fetal growth restriction (<32 weeks), or multiple soft markers when no placental basis for FGR is indicated — offer CMA per SMFM, SOGC, and SOGC/CCMG guidance.

Society guideline support and recommended practices

inv-75: Diagnostic evaluation of individuals with developmental disabilities, intellectual disability, global developmental delay, autism spectrum disorder, or congenital anomalies (including prenatal structural anomalies).

Diagnostic evaluation of developmental disorders and congenital anomalies: Diagnostic evaluation of individuals with developmental disabilities, intellectual disability, global developmental delay, autism spectrum disorder, or congenital anomalies (including prenatal structural anomalies) — CMA as first‑tier testing is supported by ISCA consensus and multiple professional society publications.

ISCA consensus and ACMG technical standards

Genetic tests should be performed in CLIA-regulated laboratories.

FDA roleFDA clearance/approval information is provided for informational purposes only and is not the basis for coverage decisions.

Reference linksPolicy cites FDA webpages for device regulation and list of cleared nucleic acid-based tests (informational).

Use maternal-fetal codes (O35.x) for prenatal indications (suspected chromosomal abnormality in fetus).
Use postnatal diagnostic codes (e.g., F70, ASD, DD/ID codes) for testing ordered on infants, children, or adults.
Accurate coding supports prior authorization and medical necessity reviews.

Documentation Required

Prior authorization—documentation expectations — Provide supporting clinical documentation and evidence of informed consent/genetic counseling with prior authorization requests.

When prior authorization is required, include documentation that demonstrates the indication meets policy criteria and that informed consent and genetic counseling were addressed. UnitedHealthcare may require submission of test reports, ultrasound findings, family history, and prior targeted testing results.

Document indication that matches medical necessity criteria (e.g., fetal structural abnormality on ultrasound, stillbirth, DD/ID, ASD, multiple congenital anomalies).
Include ultrasound reports, operative/invasive procedure notes (amniocentesis/CVS), and pathology reports when relevant.
Attach prior genetic testing results (targeted syndrome testing, Fragile X, biochemical testing) if performed.
Document pretest discussion, informed consent, and whether comprehensive genetic counseling was provided or offered.

Documentation Required

Laboratory regulation and prior authorization — Policy references CLIA/FDA informational resources for laboratory regulation; laboratories should provide validation/method details when required for prior authorization or review.

Clinical laboratories performing CMA must comply with federal laboratory regulations (CLIA) and follow applicable FDA informational resources for test platforms. Laboratories should be able to provide validation, methodology, and performance characteristics if requested during coverage review.

CLIA certification is expected for laboratories performing CMA.
Provide test methodology (aCGH, SNP array, low-pass sequencing) and limits of detection when requested.
If relying on FDA-cleared/approved tests or platforms, include relevant device/test identifiers in submissions.

Prior Authorization

Prior authorization and criteria — The policy is used to assist in coverage determinations; follow UnitedHealthcare prior authorization processes and any InterQual or state-specific criteria.

This policy assists in coverage determinations but does not replace UnitedHealthcare prior authorization processes or applicable InterQual/state-specific requirements. Follow payer-specific prior authorization procedures and submit required documentation to establish medical necessity per the criteria below.

Follow UnitedHealthcare prior authorization submission pathways and timelines.
If InterQual or state Medicaid criteria apply, ensure documentation aligns with those rules.
Coverage decisions will reference the member's federal, state, or contractual benefit requirements; these govern if conflicts exist.

Denial Risk

Non-covered indications — Testing is considered unproven and not medically necessary for populations and conditions other than the specified indications.

CMA is considered unproven and not medically necessary for indications outside the specified coverage criteria. Do not submit prior authorization requests for non-covered indications without clinical justification that aligns with policy exceptions.

Testing is not medically necessary for populations/conditions not listed as covered (e.g., routine population screening without clinical indication).
Absence of documented clinical indications (e.g., no structural anomalies, no DD/ID/ASD, no stillbirth workup) may lead to denial as investigational.

Denial Risk

Consent and counseling deficiencies — Lack of appropriate and informed consent, or inadequate documentation of genetic counseling, may limit testing value and affect coverage.

Lack of appropriate informed consent or inadequate documentation of pretest genetic counseling may limit the value of testing and is a circumstance that can affect coverage. Ensure consent and counseling are documented in the medical record prior to ordering CMA.

Document that comprehensive pretest genetic counseling was provided, including discussion of benefits, limitations, VUS, non-paternity, and adult-onset findings.
Record who provided counseling (genetics professional or qualified clinician) and that informed consent was obtained.
If counseling was offered but declined, document the offer and patient decision.

Documentation Required

Counseling and consent documentation — Document comprehensive pretest and posttest genetic counseling (benefits, limitations, potential for VUS, non-paternity, consanguinity, and follow-up) and informed consent.

Document both pretest and posttest genetic counseling and informed consent in the medical record. Counseling should cover potential outcomes (pathogenic findings, variants of uncertain significance, incidental adult-onset findings), implications for family members, and next steps for abnormal results.

Record that counseling was offered/provided and include a summary of topics discussed.
For prenatal testing, document discussion of potential to identify non-paternity and consanguinity, and options for reporting incidental findings.
Include documentation of parental testing recommendations when a CNV of uncertain significance is found.

Documentation Required

Genetic counseling and consent documentation — Genetic counseling (pre- and post-test) and documentation of informed consent are recommended/required by multiple specialty guidelines.

Genetic counseling by a qualified professional is strongly recommended and often required by specialty guidelines prior to CMA. Ensure the record reflects that counseling was provided or that a referral was made to genetics services.

Document the counseling provider and nature of counseling (in-person, telehealth, or documented phone discussion).
If genetic counseling resources are limited, document attempts to arrange counseling and informed consent discussions completed by the ordering clinician.

Note

Reference contractual requirements — When deciding coverage, reference the member's federal, state, or contractual benefit requirements; these govern if they conflict with this policy.

When evaluating coverage, reference the member's federal, state, and contractual benefit requirements. If those requirements differ from the policy, the federal/state/contractual requirements govern coverage.

Verify coverage limitations, state mandates, and Medicaid-specific rules prior to ordering/testing.
Document adherence to contractual or state-mandated coverage rules in the authorization submission when relevant.

Prior Authorization

Testing sequence for invasive prenatal diagnosis — When invasive prenatal diagnostic testing is performed for fetal structural abnormalities, CMA may replace conventional karyotype as the primary test.

When invasive prenatal diagnostic testing is performed for fetal structural abnormalities, CMA is recommended as the primary test and may replace conventional karyotype. Submit ultrasound and invasive procedure documentation when requesting CMA for prenatal indications.

For fetuses with one or more major structural anomalies on ultrasound, CMA is recommended and typically can replace karyotype.
If invasive sampling (amniocentesis, CVS) is performed, include procedure notes and ultrasound findings to support medical necessity.
In structurally normal fetuses undergoing invasive testing, either karyotype or CMA may be appropriate; document the rationale for test selection.

Documentation Required

Targeted testing before CMA when syndrome suspected — When a recognized genetic syndrome is suspected, targeted testing for that syndrome is recommended first; if negative, CMA and Fragile X testing are indicated.

If a recognized genetic syndrome is suspected based on clinical features, targeted molecular testing for that syndrome should generally be performed first. If targeted testing is negative or not diagnostic, proceed to CMA (and Fragile X testing when indicated) as next-line testing.

Order syndrome-specific testing (e.g., FMR1 for Fragile X, PTEN, Rett testing) when clinical phenotype suggests a well-delineated syndrome.
If targeted testing is negative or inconclusive, document this and consider CMA and/or additional broader testing (WES/WGS) as appropriate.
Provide documentation of clinical rationale and prior testing when seeking authorization for CMA after negative targeted testing.

Intellectual Disability

DefinitionIntellectual Disability: a condition diagnosed before age 18 characterized by below-average intellectual function and lack of skills necessary for daily living.

Age of diagnosisDiagnosis occurs before 18 years of age (MedlinePlus, 2020).

Clinical relevanceAn indication for CMA when a specific genetic syndrome is not identified by clinical evaluation alone.

Well‑Delineated Genetic Syndrome

DefinitionWell-delineated genetic syndrome: a recognizable collection of traits or abnormalities that tend to occur together and are associated with a specific disease.

ExamplesExamples include Down syndrome, Turner syndrome, Rett syndrome, Prader-Willi syndrome, Marfan syndrome, neurofibromatosis type 1, Williams syndrome, trisomy 13 and 18, Klinefelter syndrome, osteogenesis imperfecta.

Implication for testingWhen such a syndrome is strongly suspected, targeted syndrome-specific testing is recommended first before CMA.

CMA (chromosome microarray analysis)

DefinitionChromosome microarray analysis (CMA) — laboratory testing using array comparative genomic hybridization (aCGH) and/or single‑nucleotide polymorphism (SNP) array to identify copy number variations (deletions/duplications) across the genome.

ScopeMay be targeted to specific genomic regions or performed genome‑wide; used for prenatal and postnatal diagnosis of chromosomal abnormalities, developmental disorders, and congenital anomalies.

LimitationsCMA detects unbalanced CNVs but may not detect balanced rearrangements or certain other abnormalities; interpretation relies on databases and may yield VUS requiring parental testing.

CNV (copy number variation)

DefinitionCopy number variation (CNV): an alteration that includes deletion and/or duplication of one or more sections of DNA which may be benign or pathogenic.

DetectionDetected by aCGH or SNP array approaches that quantify copy number differences between an individual and a control/reference.

Clinical significanceCNVs can underlie congenital anomalies, developmental delay, intellectual disability, and other neurodevelopmental disorders; databases are used to classify pathogenicity.

CMA (chromosomal microarray analysis)

Test descriptionCMA is a molecular cytogenetic test (including array‑CGH or SNP‑based arrays) that detects submicroscopic copy number variants and some regions of homozygosity.

MethodsIncludes array comparative genomic hybridization (aCGH), SNP array, and other cytogenomic approaches; requires appropriate analytic methods and reference databases for interpretation.

Clinical applicationsUsed in prenatal diagnosis (requires invasive sampling for fetal DNA) and postnatal evaluation of developmental disabilities, congenital anomalies, and neurodevelopmental disorders.

SNP‑based CMA

DefinitionSNP‑based CMA: a form of chromosomal microarray that uses single‑nucleotide polymorphism probes to detect CNVs and regions of homozygosity.

AdvantagesSNP arrays can detect regions of homozygosity (which may suggest uniparental disomy or consanguinity) and in some studies identified more anomalies than karyotype in selected fetal indications.

Use casesUsed in prenatal evaluation (with invasive sampling) and postnatal diagnostic testing for developmental disorders and congenital anomalies.

CMA — first‑tier test note

First‑tier recommendationCMA is recommended as a first‑tier diagnostic test for individuals with developmental disabilities, intellectual disability, autism spectrum disorder, or congenital anomalies (ISCA/ACMG consensus).

RationaleCMA provides higher resolution than karyotype for unbalanced chromosomal abnormalities and increased diagnostic yield in these indications.

Follow‑up testingIf CMA is negative and a specific syndrome is suspected, perform targeted gene testing; abnormal CMA results may require parental testing and additional cytogenetic studies.

VUS reporting thresholds (prenatal)

Prenatal VUS reporting guidanceSome professional guidelines recommend not reporting VUS smaller than 500 Kb deletions or 1 Mb duplications in the prenatal setting.

Reporting of larger VUSVariants above these size thresholds should be reported only if there is significant evidence the region may be pathogenic.

Parental/consent considerationsGenetic counseling and parental decisions regarding reporting of incidental/secondary findings should be obtained as part of informed consent.

CMA first‑tier recommendation

ISCA/ACMG recommendationChromosomal microarray (CMA) is recommended as the first‑tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Clinical pathwayCMA may be followed by specific gene testing if CMA results are negative and a particular syndrome is suspected.

Supporting guidanceRecommendations cited include ISCA consensus (Miller et al., 2010) and ACMG practice resources/technical standards.

Regulatory context (CLIA/FDA)

CLIA regulationGenetic tests are regulated under the Clinical Laboratory Improvement Amendments (CLIA) of 1988; testing should be performed in CLIA‑regulated laboratories.

FDA informational roleFDA clearance or approval information is provided for informational purposes only; FDA approval alone is not a basis for coverage decisions.

Guidance linksPolicy references FDA webpages for device regulation and lists of cleared nucleic‑acid based tests as informational resources.